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Abstract
Background: Suture-line hemostasis, reinforcement of friable tissue, and adhesion prevention are
key concerns for patients undergoing cardiac surgery for aortic reconstruction. Failure to secure
hemostasis at anastomotic junctures and reinforce fragile tissue may lead to increased blood loss,
additional blood product requirements, increased operative time, and, in extreme cases,
reoperation. Patients with aortic pathology may also be at higher risk for reoperation, and adhesion
formation from prior surgery is an added risk at resternotomy. The advent of high-pressure
sealants has been of benefit in helping to alleviate these perioperative challenges.
Methods: The author utilizes two high-pressure sealants for aortic reconstructive procedures.
The first is made of two polymers of polyethylene glycol (PEG) [Coseal®, Baxter Healthcare,
C o r p o r a t i o n ] ,  a n d  i s  u s e d  t o  secure anastomotic suture-line hemostasis and for adhesion
prevention. The second is a bovine serum albumin-glutaraldehyde (BSAG) glue [BioGlue®,
CryroLife, Inc.], used for the repair of dissected aortic tissue and in reinforcing ("tanning") fragile
aortic tissues. The techniques for application in select aortic reconstruction procedures are
described.
Results: To substantiate the hemostatic clinical benefit observed by the author, 60 consecutive
major thoracic aortic operations in 57 patients in whom PEG sealant was used were retrospectively
reviewed. Although comparisons with other agents were not performed for this descriptive report,
bleeding results were very favorable for these types of operations. The strong clinical impression
is that topical hemostatic application of PEG sealant to anastomotic suture lines is helpful in
preventing bleeding.
Conclusion:  In major aortic reconstructive procedures the need for anastomotic sealing
performance, reinforcement of friable tissues, and adhesion prevention should not be underrated.
High-pressure surgical sealants represent an important surgical adjunct, and the author has found
the use of both PEG sealant and BSAG glue advantageous in aortic reconstruction and repair.
Background
"Chance fights ever on the side of the prudent." – Euripides
While mastery of the technical skills required to perform
cardiac surgery may progress at a rapid pace, we are ever at
the mercy of the coagulation cascade when seeking a suc-
cessful operative outcome. Awareness of this truth has
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become especially poignant to cardiac surgeons following
the removal of aprotinin from our armamentarium [1].
Repair and reconstruction of the aorta are major cardiac
surgical procedures which often require implantation of
prosthetic graft materials primarily composed of Dacron,
which can be prone to recalcitrant bleeding at anasto-
motic sites [2,3]. The lability of the hemostatic situation is
further exacerbated by intraoperative anticoagulation
therapy required for cardiopulmonary bypass (CPB) and/
or coagulation consequences of deep hypothermic circu-
latory arrest (DHCA) [4,5]. The friable, thin tissue often
seen in aneurysm and connective disease patient popula-
tions, dissected aortic tissues, and porosities/tracks left by
the larger needles required to suture thick aortic tissue
may also be factors that contribute to increased blood loss
in aortic reconstructive procedures. Failure to secure
hemostasis at anastomotic junctures may lead to
increased blood loss, additional blood product require-
ments, increased operative time and, in extreme cases,
reoperation [2-4,6-8].
High pressure sealants: Clinical uses and properties
Anastomotic suture-line hemostasis
The advent of high-pressure sealants has been of benefit in
helping to alleviate the perioperative challenges
described, especially when operating on the aorta
[2,3,6,7,9,10]. Out of the many options available for
securing hemostasis at the anastomotic suture-line, the
author often utilizes a surgical sealant made of two poly-
mers of polyethylene glycol (PEG) [Coseal®, Baxter
Healthcare Corporation][10]. This sealant produces an
adherent, nearly clear, gel-like pseudo-clot at the site of
application, which requires no participation of the coagu-
lation cascade whatsoever. Thus, this sealant can be effec-
tive even in the face of marked deficiencies in the patient's
intrinsic coagulation mechanism. One may use either a
spray device which requires a separate pump [Fig 1A, B],
or opt for a self-contained standard applicator [Fig 1C].
The polymers gel within five seconds and set within 60
seconds. The result is a flexible, clear, degradable hydrogel
that seals and adheres to tissues (even irregular anasto-
motic structures) to which it is applied [Fig
2][2,3,6,7,9,10].
The sealant remains flexible and does not restrict move-
ment of surrounding structures; however, it maintains a
tight seal through covalent tissue bonds even under the
influence of high pressures in vessels such as the aorta
(demonstrated to seal leak pressures of 660 ± 150 mmHg
in porcine models) [2,3,6,7,9,10]. In a study conducted to
compare the mechanical properties of surgical glues used
in aortic root replacement, PEG sealant demonstrated
hemostatic efficacy while remaining flexible and compli-
ant. Thus, it allows for normal physiologic dilation with-
out contributing to elevated wall stress by stiffening
surrounding tissues which may weaken tissue structure
and potentiate late pseudoaneurysm formation [11].
Repair of dissected aortic layers
Bovine serum albumin-glutaraldehyde (BSAG) glue
[BioGlue®, CryroLife, Inc.] has adhesive as well as sealant
properties. It is provided in a self-contained applicator
with optional tip extenders [12]. BSAG glue begins to
polymerize within 20 to 30 seconds, reaches its bonding
strength within two minutes, and is very useful in repair-
A) Polyethylene glycol (PEG) surgical sealant (Coseal®) spray  applicator Figure 1
A) Polyethylene glycol (PEG) surgical sealant 
(Coseal®) spray applicator. B) "Easy Spray" regulator 
used with spray applicator. C) Self-contained standard appli-
cator. (Photos courtesy of Baxter Healthcare Corporation).
A) PEG sealant following polymerization with semi-opaque  hydrogel consistency Figure 2
A) PEG sealant following polymerization with semi-
opaque hydrogel consistency. B) Sealant is pliable, and 
does not restrict the movement of surrounding tissues. It 
maintains a secure seal even under the influence of high pres-
sures exerted by the aorta.Journal of Cardiothoracic Surgery 2009, 4:27 http://www.cardiothoracicsurgery.org/content/4/1/27
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ing dissected aortic layers and in reinforcing ("tanning")
fragile aortic tissues. The author is a strong advocate for
the use of BSAG glue in the setting of acute aortic dissec-
tion, or in situations of severe tissue fragility, in which the
tissue tanning and strengthening properties of the glutar-
aldehyde can be life-saving [4]. It has been reported as a
means of securing suture-line hemostasis, however, this
use is not recommended by the author as the potential for
product leakage through needle-holes may lead to throm-
bosis or embolization [13,14]. Adverse events associated
with the use of BSAG glue have also been reported and
include phrenic nerve damage leading to diaphragmatic
paralysis, false aneurysm, and local and distant complica-
tions from embolized particles released into the vessel
lumen through needle holes and as a result of over-appli-
cation of material [15-17].
Adhesion prevention
One key property of PEG sealant in cardiac surgery is that
the hydrogel swells to 4× the initial volume within 24
hours of application, allowing it to act effectively as a
mechanical barrier to cellular infiltration keeping tissues
separated while the inflammatory process subsides. By
separating tissues during the healing process, PEG sealant
has been shown to be effective at preventing surgical
adhesions in both cardiac and gynecologic surgery [18-
20]. This is an especially important consideration in
patients in whom reoperation is anticipated (pediatric
patients, younger adult patients, etc.) or expected (when
placing left ventricular assist systems), as the potential for
formation of dense and tenacious adhesions makes rester-
notomy difficult and potentiates injury to structures such
as the aorta, right ventricle, right atrium, innominate vein,
innominate artery, aortocoronary grafts, etc. [21]. Adhe-
sions may also potentially constrict the heart, potentiate
right ventricular dysfunction, and/or be a factor in the
promotion of graft occlusion [22-25]. Clinicians should
be aware that PEG sealant is approved for the indication
of adhesion prevention in Europe, however, approval for
use in this indication has not yet been granted in the
United States.
The optimal duration for which early adhesions must be
prevented to reduce longer term scar formation is
unknown; however, evidence suggests that even 6 to 12
hours may be sufficient [26,27]. The PEG sealant swells to
4× the initial volume within 24 hours of application,
allowing it to act effectively as a barrier to cellular infiltra-
tion. However, one must be careful to apply only a thin,
uniform layer of sealant as thicker applications do not
increase benefit and may lead to mass effects or mechani-
cal compression complications [28].
Biocompatibility and biodegradability
PEG sealant and BSAG glue contain reactive substances to
adequately perform their intended function. Both prod-
ucts adhere to tissues by covalent chemical bonds [29].
Thus, a chemical reaction takes place between the product
and the tissue surface, and a foreign-body reaction to the
implanted material is inevitable. The degree of the
response is related to many factors including implanta-
tion site, reactivity of the patient, and could possibly be
related to the type and amount of product used. PEG seal-
ant is synthetically-derived, and there are no human or
bovine blood-based additives. It is therefore, highly bio-
compatible and the observed reactivity has been consid-
ered minimal [30]. BSAG glue contains a small amount of
bovine additive, however, reactivity seems to be related to
the release of glutaraldehyde. One study indicated that
polymerized BSAG glue may induce cytotoxic effects both
in vitro and in vivo, and recommends that it be restricted
to the aortic dissection procedure as other tissues are sen-
sitive to the glutaraldehyde released [31].
Biodegradability of surgical sealants is a critical factor and
directly relates to the long-term effects. PEG sealant and
BSAG glue both degrade following implantation, how-
ever, the rates and mechanisms by which this occurs are
very different [29]. The resorption rate of PEG sealant is
fairly rapid. In an in vitro study, hydrolytic degradation
was demonstrated after several days of incubation at 37°C
[30]. In vivo, PEG sealant degraded within < 30 days of
implantation and could not be discerned grossly or histo-
logically at 30 days [7]. Because the major component of
BSAG glue is albumin, it degrades via proteolysis and is
resorbed slowly [29]. Histologically, the material was
detectable after 1 year in a goat model [32].
Methods
General application techniques
For PEG sealant and BSAG glue, the suture line must be
absolutely dry before application. Careful drying with
sponges usually suffices. If necessary, sponge drying may
be supplemented by insufflations of CO2 just before seal-
ant application. When using PEG sealant, the spray appli-
cator may be used to dry the surface by covering the hole
at the upper end without depressing plunger (to extrude
sealant). A thin, uniform layer of sealant is optimal [Fig
3]. Excessive sealant application will not increase benefit
and may lead to adverse effects.
To insure uniform coverage, the treatment site may be
rotated to facilitate exposure of all surfaces and/or the tip
of the applicator may be bent. The sealant should be
applied in one continuous motion for thorough, even
coverage, moving quickly rather than pausing, which may
cause the tip to clog. Extra applicator tips should be made
available for rapid replacement should clogging occur.Journal of Cardiothoracic Surgery 2009, 4:27 http://www.cardiothoracicsurgery.org/content/4/1/27
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Following polymerization, PEG sealant remains pliable. If
required, reinforcement sutures at the anastomic suture
line can be placed through it, though this is seldom nec-
essary. One should remember that surgical sealants and
adhesives are not a replacement for meticulous surgical
technique and, in spite of rapid polymerization, an inad-
equate repair may allow for entry of the sealant into the
vessel lumen.
Ascending aortic reconstruction
There are several disorders that necessitate reconstruction
in both the ascending aorta and aortic arch. The most
common are ascending aneurysm, ascending dissection,
arch aneurysm, and descending pathology requiring for-
mal aortic arch replacement. The most serious complica-
tions of aortic aneurysm are aortic dissection and rupture
which are inherently lethal conditions. The most impor-
tant concern should be patient survival [33]. If the patient
survives the acute episode this constitutes a success,
regardless of later onset of further aortic problems. The
early mortality for urgent operation for acute aortic dissec-
tion ranges from 15% to 25%, depending largely on insti-
tutional experience [4,33]. While such results represent
dramatic improvement from earlier eras, surgical science
still has room for progress in the treatment of this chal-
lenging disorder. One of the critical elements to achieving
patient survival is complete hemostasis.
Supracoronary tube and composite graft reconstruction
The author's preferred technique for operations on the
ascending aorta is via two-stage atrial/femoral artery can-
nulation and perfusion, arresting the heart through ante-
grade and retrograde cardioplegia, cross-clamping the
aorta, and performing the proximal anastomosis. The
aorta is then unclamped under deep hypothermic circula-
tory arrest (DHCA) and the operation proceeds with the
distal anastomosis. Performing the proximal anastomosis
first is preferred by the author, as the required exposure
deep in the aortic root is more difficult after the distal graft
is attached. Perfusion is then resumed using the original
femoral cannula. The author has previously published on
the safety of resuming perfusion through this route even
in aortic dissection [33,34]. In the minority of patients
with descending atheroma (unusual in this patient group)
axillary cannulation is used.
Prior to application of the surgical sealant, which is the
final step in securing the anastomotic suture-line, the
author also recommends reinforcement of posterior anas-
tomotic suture lines (both in a tube graft, distal in a com-
posite graft), with interrupted, single-pledgeted sutures as
this area becomes inaccessible following anastomotic clo-
sure. Although it does take a bit of extra time, the author
considers these minutes well-spent in terms of the added
strength provided to the arterial closure. A Teflon felt strip
is then applied circumferentially as the anastomosis pro-
ceeds with 3-0 Prolene sutures. MH needles are recom-
mended to adequately penetrate dense aortic tissue and
facilitate grasping. Finally, in the case of composite graft
reconstruction, placement of felt washers to secure the
coronary buttons is recommended [35].
Repair of dissected aortic layers
For an acute ascending aortic dissection, the separated lay-
ers of the aortic wall (the "intima" and the "adventitia")
are re-approximated prior to anastomosis to the pros-
thetic graft via a "sandwich" technique of Teflon strips
placed inside and outside the vessel wall secured by radi-
ally-oriented horizontal mattress sutures. The felt adds
considerably to the strength of the reconstituted aortic
wall. As previously discussed, the repair may also be sup-
plemented with BSAG glue used sparingly to produce
adherence between layers and to strengthen the fragile tis-
sues through its tanning properties.
Sealing of the proximal anastomosis
Following proximal anastomotic completion of a com-
posite graft, the PEG surgical sealant is applied via a spray
or standard applicator circumferentially (360°) to the
anastomotic juncture and coronary buttons [see Addi-
tional file 1]. Sealing is performed immediately following
completion of the proximal anastomosis, as this area will
disappear from view after the heart is reperfused [see Fig
3A]. To insure that a thin, uniform layer of sealant is
applied to the anastomotic site, the graft may need to be
carefully shifted and the applicator rotated circumferen-
tially. Keep in mind that thicker applications of sealant
will not increase benefit, and may lead to longer polymer-
ization time and/or mass effect complications due to
anticipated swelling of product up to 4× its volume [28].
As the distal portion of the graft remains open at this stage
in the operation, one should take care (especially when
using the spray applicator) not to allow product to enter
the vessel lumen.
A): Intraoperative view of PEG sealant coverage of proximal  and B) distal aortic anastomoses utilizing a self-contained,  standard applicator Figure 3
A): Intraoperative view of PEG sealant coverage of 
proximal and B) distal aortic anastomoses utilizing a 
self-contained, standard applicator.Journal of Cardiothoracic Surgery 2009, 4:27 http://www.cardiothoracicsurgery.org/content/4/1/27
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Sealing of the distal anastomosis
Following completion and sealing of the proximal aortic
anastomosis, the distal anastomosis is performed in like
fashion with posterior pledgets, a circumferential Teflon
strip, and PEG sealant [see Fig. 3B]. By reaching around
the graft and gently mobilizing it, a near 360° application
can be achieved. If necessary, the applicator tip may be
bent to provide coverage in hard-to-reach areas.
If product is still remaining in the applicator following the
proximal anastomosis, it may be used for the distal anas-
tomosis. Depending on the coverage area, one should
choose the appropriate amount to have mixed and ready
for sealing. When using a spray tip, application may be
easily resumed. When using a self-contained applicator, a
tip replacement may be required, as the tip tends to clog
following a pause in the procedure.
Simultaneous sealing of the proximal and distal anastomoses
In some instances, as for a simple tube graft, it may be
appropriate to seal both the proximal and distal anasto-
moses simultaneously following completion of the distal
anastomosis. The author sometimes prefers to reperfuse
the aorta following removal from DHCA, and complete
rewarming and weaning from bypass, thus allowing
native hemostatic mechanisms to act. Subsequently the
area is dried with sponges in anticipation of sealant appli-
cation, which is done just before chest closure. This
sequence is appropriate for anastomoses that are still well
exposed after the heart is filled and bypass is discontin-
ued. For patients with reoperative potential, an added
benefit may be derived from utilizing the spray applicator
within the chest cavity/surgical site for adhesion preven-
tion as previously described.
Aortic arch replacement
The author frequently modifies the technique for arch
replacement from the standard method. This is accom-
plished by confining the Carrel patch to the innominate
and left carotid arteries. This makes for a more managea-
ble patch, located close to the operator and fully accessi-
ble for subsequent hemostasis. This factor of accessibility
becomes even more important in the case of acute dissec-
tion of the aortic arch, as the dissected aorta is friable, and
bleeding can frequently ensue, requiring tension-free
exposure and placement of additional sealant and sutures
if necessary. The smaller two-vessel procedure meets all of
these requirements for accessibility. Also, this smaller
patch can be anastomosed in relatively short order, thus
decreasing the length of cerebral ischemia and DHCA.
After the patient is weaned from bypass, a side-arm graft
to the subclavian artery is placed. In the case of patient
instability, the subclavian artery can be simply ligated;
ischemic problems would be rare with such a proximal
ligation of the subclavian artery as there are extensive col-
Table 1: Demographic and perioperative data for patients 
receiving PEG sealant
Variables Data
Total Patients 57
Total Operations 60
Total Reoperations (2 in same patient) 3 (5%)
Gender
Male 41 (72%)
Female 16 (28%)
Age (years)
Mean 58
Range 26–89
Weight (kilograms)
Mean 91
Range 50–147
pRBC Transfusion Requirements (mean units)
Intraoperative 0.8
Postoperative 0.7
Procedures without pRBC transfusion 28 (47%)
CPB Time (minutes)*
Mean 137
Range 27–210
Aortic Cross-Clamp (minutes)*
Mean 106
Range 25–154
DHCA Time (minutes)*
Mean 31
Range 19–52
Abbreviations: pRBC: packed red blood cells; CPB: cardiopulmonary 
bypass; DHCA: deep hypothermic circulatory arrest.
*Mean/range calculated for those procedures in which CPB, DHCA, 
and/or aortic cross-clamp.Journal of Cardiothoracic Surgery 2009, 4:27 http://www.cardiothoracicsurgery.org/content/4/1/27
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laterals via the thyrocervial trunk, internal mammary
artery, and other routes.
PEG sealant is applied to the Carrel patch and to all anas-
tomotic suture-lines. As mentioned previously, reinforce-
ment sutures may still be placed following application
and polymerization of the product if one notes that
suture-line hemostasis has not been secured following
reperfusion.
Results
Cardiac surgeons have endeavored to identify new proto-
cols and adjunctive methodologies for reducing perioper-
ative blood loss and the use of exogenous blood products,
especially in high-risk procedures. To substantiate that
PEG sealant has been of benefit in this regard, the experi-
ence of 57 patients (41 male/16 female) patients were
examined [Tables 1, 2]. We reviewed 60 consecutive
major thoracic aortic operations in patients who received
PEG sealant from June through December of 2008 (fol-
lowing the removal of aprotinin). In the majority of
patients, PEG sealant was used in conjunction with ami-
nocaproic acid [Amicar®, Xanodyne Pharmaceuticals,
Inc.].
Although comparisons with other agents were not per-
formed for this descriptive report, the author feels that
bleeding results were very favorable for these types of
operations. The strong clinical impression is that topical
hemostatic application of PEG sealant to anastomotic
suture lines is helpful in preventing bleeding, especially in
the current post-aprotinin era.
Discussion
Although a number of choices are available for suture-line
hemostasis and repair of dissected aortic tissue, each has
specific advantages and liabilities. PEG sealant and BSAG
glue are fundamentally different than traditional hemo-
static interventions because they are independent of the
blood coagulation cascade. This property makes them
ideal for cardiac surgery because they remain effective
even in patients with severe coagulation deficiencies due
to preoperative exposure to prescribed anticoagulants and
herbal/vitamin supplements as well as intraoperative
heparinization for CPB and use of DHCA.
In addition to the many challenges already discussed in
terms of securing hemostasis at anastomotic suture lines
in aortic reconstruction, there has been a steady increase
in the use of herbal and vitamin supplements that inter-
fere with the coagulation process. The most notable are
ginseng, gingko biloba, and omega-3 fatty acids [36-40].
The estimated prevalence of dietary-supplement use
among US adults was 73% in 2002 and this rate continues
to increase annually [36]. Many patients do not consider
the use of herbal and vitamin supplements to be relevant
to medical practice. Consequently, they may not tell their
clinicians about use of these substances [40]. Thus, it is
Table 2: Procedural details for patients receiving PEG sealant
Procedure/Reconstruction Number of Patients (n = 57)
Aortic valve replacement/aortoplasty 10 (17%)
Root-sparing ascending aorta 5 (8%)
Composite ascending aorta 17 (28%)
Root-sparing ascending aorta/hemiarch 6 (10%)
Composite ascending aorta/hemiarch 4 (7%)
Root-sparing ascending aorta/arch 6 (10%)
Composite ascending aorta/arch 2 (3%)
Descending aorta/reconstruction 2 (3%)
Other 8 (14%)
Total Operations 60
Note 1: Six (6) procedures involved associated CABG.
Note 2: Three (3) procedures (other) were reoperations for bleeding.Journal of Cardiothoracic Surgery 2009, 4:27 http://www.cardiothoracicsurgery.org/content/4/1/27
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prudent for clinicians to routinely identify which supple-
ments their patients may be using.
In addition to herbal and vitamin supplements, the wide-
spread use of short or long-term anticoagulation therapy
(e.g., clopidogrel, warfarin, aspirin, etc.) has also led to
challenges in securing hemostasis in cardiac surgical pro-
cedures [41,42]. With recommended loading doses of
clopidogrel as high as 900 mg in select patients [43], oper-
ating on patients on an emergent or elective basis in
whom clopidogrel and other anticoagulant therapies are
not discontinued in advance of surgery is a major cause
for concern. These medications make coagulation in any
surgical patient quite tenuous. In the case of clopidogrel,
a recent study indicated that surgical patients taking this
drug within 3 days of their procedure required almost
twice as many reoperations [42].
In addition to suture-line hemostasis, PEG sealant has
been shown to be effective at preventing adhesion forma-
tion in cardiac and gynecologic surgery [18-20]. However,
although PEG sealant has been studied and is licensed for
adhesion prevention in Europe, it has not yet been
licensed for this indication in the United States, so clini-
cians should evaluate use in this capacity carefully.
Conclusion
The best outcome, in terms of appropriate hemostasis in
cardiac surgery, resides in prevention and prudence. In
major aortic reconstructive procedures the need for anas-
tomotic sealing performance, adhesion prevention, and
reinforcement of friable tissues should not be underrated.
High-pressure surgical sealants represent an important
surgical adjunct, and the author has found the use of both
PEG sealant and BSAG glue advantageous in aortic recon-
struction and repair.
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